Professor Toni Choueiri

Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute

Lifetime Achievement International Track

Toni K. Choueiri, MD is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. He is the Medical Director, International Strategic Initiatives at DFCI and past President of the Medical Staff at DFCI. He received multiple national and international awards and in addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.

Prof. Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). In a series of New England Journal of Medicine articles on which he was either first or senior author, Prof. Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of RCC and led to the approval of several novel cancer therapies. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy. He has also contributed to our understanding of the underlying biology and rationale for therapies in rare histological variants of RCC such as papillary, translocation, and sarcomatoid RCC.

Prof. Choueiri has received research funding from the NCI, the Department of Defense (DOD), and industry partners. His work has been published in prestigious journals such as the New England Journal of Medicine, The Lancet, Science and Nature Medicine. He has over 750 PubMed-indexed publications, has an H-Score of 139 (Google scholar, 10/2023) and is the lead investigator of multiple national and international phase I-III clinical trials in Cancer.